Neuroblastoma is the most common type of childhood cancer and its incidence is gradually increasing across the world. The exact etiological factor contributing to neuroblastoma remains undefined. However, the rising birth rate is a major contributor to the growing incidence of neuroblastoma. The incidence of neuroblastoma is increasing in developed as well as developing countries. Thus, the rising incidence of neuroblastoma is one of the driving factors for the market growth. Technavio’s analysts have predicted that the neuroblastoma drugs market will register a CAGR of over four percent by 2023.
Market Overview
Growing Demand for Anti-GD2 Antibodies
The identification of the therapeutic targets on tumor cells or within the signaling cascade that leads to tumor growth is a promising field in cancer research. GD2 (O-acetyl-GD2 ganglioside) has been identified as a cell surface antigen that is overexpressed in neuroblastoma. These drugs do not pose any cytotoxic effects in the body. Therefore, physicians are switching toward prescribing anti-GD2 monoclonal antibodies for the treatment of neuroblastoma.
High Cost of Treatment
Children with neuroblastoma typically undergo many rounds of complex and intensive treatment, comprising several cycles of chemotherapy. The long duration increases the treatment costs. Drugs for the treatment of neuroblastoma, especially immunotherapy drugs, are considerably expensive. This increases the manufacturing costs of these drugs and subsequently the prices.
Competitive Landscape
The market appears to be moderately concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
